-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Insiders, Selling CN¥55m Worth of Stock Earlier This Year Was a Smart Move.
For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Insiders, Selling CN¥55m Worth of Stock Earlier This Year Was a Smart Move.
Even though Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) stock gained 19% last week, insiders who sold CN¥55m worth of stock over the past year are probably better off. Holding on to stock would have meant their investment would be worth less now than it was at the time of sale. Thus selling at an average price of CN¥6.12, which is higher than the current price, may have been the best decision.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
See our latest analysis for Jacobio Pharmaceuticals Group
Jacobio Pharmaceuticals Group Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the insider, Shaojing Hu, sold HK$30m worth of shares at a price of HK$6.00 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$5.25. So it is hard to draw any strong conclusion from it.
Over the last year, we can see that insiders have bought 223.80k shares worth HK$2.3m. But insiders sold 9.00m shares worth HK$55m. In total, Jacobio Pharmaceuticals Group insiders sold more than they bought over the last year. They sold for an average price of about CN¥6.12. Insider selling doesn't make us excited to buy. But the selling was at much higher prices than the current share price (HK$5.25), so it probably doesn't tell us a lot about the value on offer today. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:1167 Insider Trading Volume August 26th 2022If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Jacobio Pharmaceuticals Group Insiders Are Selling The Stock
Over the last three months, we've seen significant insider selling at Jacobio Pharmaceuticals Group. Specifically, insiders ditched HK$55m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
Insider Ownership Of Jacobio Pharmaceuticals Group
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Jacobio Pharmaceuticals Group insiders own 26% of the company, currently worth about HK$1.0b based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Do The Jacobio Pharmaceuticals Group Insider Transactions Indicate?
Insiders sold Jacobio Pharmaceuticals Group shares recently, but they didn't buy any. Zooming out, the longer term picture doesn't give us much comfort. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 3 warning signs for Jacobio Pharmaceuticals Group you should be aware of, and 1 of them is a bit unpleasant.
But note: Jacobio Pharmaceuticals Group may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
即使雅可比奧製藥集團有限公司(HKG:1167)上週股價上漲19%,在過去一年中拋售了價值5500萬元人民幣股票的內部人士可能會更好。持有股票將意味着他們現在的投資價值將低於出售時。因此,以高於當前價格的6.12元的均價出售可能是最好的決定。
儘管我們不認為股東應該簡單地跟蹤內幕交易,但我們確實認為,密切關注內部人士的所作所為是完全合乎邏輯的。
查看我們對Jacobio製藥集團的最新分析
雅各比奧製藥集團去年的內幕交易
在過去12個月裏,內部人士出售的最大單筆交易是內部人士胡紹景以每股6港元的價格出售了價值3000萬港元的股票。雖然我們通常不喜歡看到內幕出售,但如果以更低的價格出售,人們更擔心的是。令人欣慰的是,此次出售的價格遠遠高於目前5.25港元的股價。因此,很難從中得出任何強有力的結論。
過去一年,我們可以看到,內部人士買入了223.8萬股,價值230萬港元。但內部人士拋售了9億股股票,價值5500萬港元。總體而言,雅各比奧製藥集團內部人士去年賣出的比購買的要多。它們的均價約為6.12元人民幣。內幕銷售不會讓我們興奮地購買。但此次拋售的價格遠高於目前的股價(5.25港元),因此它可能不能告訴我們太多關於今天的報價的價值。下面的圖表顯示了過去一年的內幕交易(按公司和個人)。如果你想知道到底是誰賣了,賣了多少錢,什麼時候賣的,只需點擊下面的圖表!
聯交所:2022年8月26日內幕交易量1167如果你像我一樣,你會的不想懷念這一切嗎?免費內部人士正在收購的成長型公司名單。
雅各比奧製藥集團內部人士正在出售股票
在過去的三個月裏,我們看到雅各比奧製藥集團進行了大量的內幕銷售。具體地説,在那段時間內,內部人士拋售了價值5500萬港元的股票,我們沒有記錄任何買入。總體而言,這讓我們有點謹慎,但這並不是一切。
雅可比奧製藥集團的內部人所有權
許多投資者喜歡查看一家公司有多少股份是由內部人士持有的。我們通常希望看到相當高水平的內部人士持股。Jacobio PharmPharmticals Group內部人士持有該公司26%的股份,按近期股價計算,目前價值約為10億港元。這種由內部人士持有的重大所有權通常確實增加了公司以所有股東的利益運營的機會。
那麼,雅可比奧製藥集團的內幕交易表明了什麼?
內部人士最近拋售了Jacobio PharmPharmticals Group的股票,但他們沒有買入任何股票。縮小來看,較長期的圖景並不會給我們帶來太多安慰。看到高內部人持股是件好事,但內部人拋售讓我們保持謹慎。雖然我們喜歡知道內部人士的所有權和交易情況,但在做出任何投資決定之前,我們也要確保考慮到一隻股票面臨的風險。一個恰當的例子:我們發現了雅各比奧製藥集團的3個警告信號你應該知道,其中一個是有點令人不快的。
但請注意:雅各比奧製藥集團可能不是最值得買入的股票。所以讓我們來看看這個免費高淨資產收益率和低負債的有趣公司名單。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧